Lung Cancer section

Lung Cancer News & Features

Mental Health Disorder Linked to Poorer Survival in NSCLC

Mental Health Disorder Linked to Poorer Survival in NSCLC

Among patients with non-small cell lung cancer (NSCLC), those with a mental health disorder appeared to have a higher risk of death.

Intermittent Hypoxia Promotes Lung Tumor Cell Aggressiveness

Intermittent Hypoxia Promotes Lung Tumor Cell Aggressiveness

IH-induced exosomes from mice significantly promote TC1 malignant properties, according to a recent study.

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.

Vandetanib Moderately Active in RET+ Advanced NSCLC

Vandetanib Moderately Active in RET+ Advanced NSCLC

Researchers report on their evaluation of the efficacy and safety of vandetanib, a kinase inhibitor of VEGFR, EGFR, and the RET-tyrosine kinase, in patients with NSCLC tumors with chromosomal rearrangements involving RET.

HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC

HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC

This study focused on determining the effectiveness of a short-term high-intensity interval training (HIIT) program to improve patients' cardiorespiratory fitness prior to NSCLC resection.

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.

Lenvatinib Shows Promising Activity in RET+ NSCLC

Lenvatinib Shows Promising Activity in RET+ NSCLC

Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.

Depression Linked to Increased Mortality in Lung Cancer

Depression Linked to Increased Mortality in Lung Cancer

Changes in depression symptoms over time are associated with differences in survival among patients with lung cancer, especially those with early stage disease.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs